CAG
MTNB icon

Crestwood Advisors Group’s Matinas BioPharma MTNB Stock Holding History

Crestwood Advisors Group’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,850
Closed -$110K – 244
2020
Q2 		$110K Hold
2,850
– – ﹤0.01% 229
2020
Q1 		$86K Hold
2,850
– – ﹤0.01% 215
2019
Q4 		$323K Buy
+2,850
New +$165K 0.01% 203

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Crestwood Advisors Group's MTNB Position: Q3 2020 in Review

Crestwood Advisors Group sold out of Matinas BioPharma (MTNB) in Q3 2020, closing a stake of 2,850 shares — an estimated $110K sold.

Crestwood Advisors Group first reported a position in MTNB in Q4 2019 and held it in 3 quarters. The position peaked at $323K in Q4 2019. 61 funds tracked by Wall St. Rank hold MTNB as of Q3 2020.

  • Crestwood Advisors Group reported no remaining Matinas BioPharma position as of Q3 2020 after selling out during the quarter.
  • Crestwood Advisors Group sold 2,850 Matinas BioPharma shares in Q3 2020, an estimated $110K.
  • Crestwood Advisors Group first reported a position in Matinas BioPharma in Q4 2019 and held it in 3 quarters.
  • Crestwood Advisors Group's Matinas BioPharma position peaked at $323K in Q4 2019.
  • 61 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2020.

Based on Crestwood Advisors Group's 13F filing for Q3 2020, filed 6 Oct 2020.